Document ID: chunk:federal_register_of_legislation:F2024C00880:front:0:p2
Version: federal_register_of_legislation:F2024C00880
Segment Type: other
Provision Reference: 
Character Range: 2792–4878

Prescription by authorised prescriber only
Part 3—Treatment doses for children
Division 1—General
9B This Part applies to children
10 Definitions relating to doses of somatropin
11 Assessment of dosage of pharmaceutical benefit
Division 2—Reclassification
12 Dose for change of treatment category (reclassification)
Division 3—Recommenced treatment
13 Dose for recommenced treatment
Part 4—Payment amounts
Division 1—Payments to suppliers that are approved hospital authorities for public hospitals
14 Payments to approved hospital authorities for public hospitals
Division 2—Payments to suppliers that are approved hospital authorities for private hospitals, approved pharmacies or approved medical practitioners
15 Payments to certain suppliers of pharmaceutical benefits
Part 5—Dispensed price
Division 1—Dispensed price for supply of a pharmaceutical benefit by a hospital authority for a public hospital
16 The dispensed price—supply by public hospital
17 Where quantity is less than a pack quantity
Division 2—Dispensed price for supply of a pharmaceutical benefit by certain suppliers
18 The dispensed price—supply by an approved hospital authority for a private hospital, an approved pharmacist or an approved medical practitioner
19 Mark‑up
20 Where quantity is less than a pack quantity
21 Dispensing fee
Division 3—Dispensed price—Other matters
22 Rounding up of dispensed price
Part 6—Patient contributions
23 Patient contributions
Part 6A—Supply to CTG registered patients by CTG suppliers
23A Application of this Part
23B Application of the CTG Special Arrangement—co‑payment and payment etc.
23C Claim for payment
Part 7—Approved Hospital Authorities
24 Modified application of section 94 approved hospital authorities
Schedule 1—Pharmaceutical benefits covered by this Special Arrangement and related information
Part 1 – Pharmaceutical benefits for treatment of children
Part 2—Pharmaceutical benefits for treatment of adults
Endnotes
Endnote 1—About the endnotes
Endnote 2—Abbreviation key
Endnote 3—Legislation history
Endnote 4—Amendment history

Part 1—Preliminary